Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Akers Biosciences Inc. (NASDAQ: AKER).

Full DD Report for AKER

You must become a subscriber to view this report.


Recent News from (NASDAQ: AKER)

Today's Research Reports on Trending Tickers: Herbalife and Akers Biosciences
NEW YORK, NY / ACCESSWIRE / April 26, 2018 / U.S. markets were mixed on Wednesday as stronger-than-expected corporate earnings offset a continuous rise in bond yields. The Dow Jones Industrial Average gained 0.25 percent to close at 24,083.83, led higher by Boeing, while the S&P 500 Ind...
Source: ACCESSWIRE IA
Date: April, 26 2018 08:30
Akers Biosciences Expands Outsourced US Distribution Capabilities for Heparin PF4 Rapid Test
THOROFARE, N.J., April 12, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces the engagement of two leading Independent Sales Representative (ISR) organiz...
Source: GlobeNewswire
Date: April, 12 2018 07:00
Free Post Earnings Research Report: AtriCure's Quarterly Revenues Jumped 11.9%; Net Loss Narrowed
Stock Monitor: Akers Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free earnings report on AtriCure, Inc. (NASDAQ: ATRC ). If you want access to this report all you need to do is sign up now by clicking the fo...
Source: ACCESSWIRE IA
Date: April, 09 2018 07:30
Akers Biosciences (AKER) CEO John Gormally on Q4 2017 Results - Earnings Call Transcript
Executives John Gormally - Chief Executive Officer Gary Rauch - VP of Finance Ben Simons - Corporate Communications Analysts James Terwilliger - Paulson Investment Co. Marc Robin - Catalyst Research Michael Clark - Private Investor Presentation Operator Good morning...
Source: SeekingAlpha
Date: April, 03 2018 15:37
Akers Biosciences down 15% premarket on FY 2017 results
Akers Biosciences ( AKER ) FY results : Revenues: $3.9M (+30.0%); Operating Loss: ($5.1M) (-54.5%); Net Loss: ($5.8M) (-75.8%); Loss Per Share: ($0.61) (unch); Quick Assets: $5.5M; CF Ops: ($5.1M) (-21.4%). More news on: Akers Biosciences Inc., Healthcare stocks news, Earnings news and co...
Source: SeekingAlpha
Date: April, 03 2018 07:14
Akers Biosciences reports FY results
Akers Biosciences (NASDAQ: AKER ): FY net loss of $5.8M More news on: Akers Biosciences Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: April, 03 2018 07:05
Akers Biosciences Reports Earnings for Fiscal Year 2017
Total Revenue Up 33% THOROFARE, N.J., April 03, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers”, “Akers Bio” or the "Company"), a developer of rapid health information technologies, reports its financial results for t...
Source: GlobeNewswire
Date: April, 03 2018 07:03
Akers Biosciences Announces Rescheduled Conference Call to Discuss Fiscal Year 2017 Earnings
THOROFARE, N.J., March 28, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, will now hold a conference call on Tuesday, April 3, 2018 at 09:00 a.m. Eastern Time t...
Source: GlobeNewswire
Date: March, 28 2018 11:20
2 Biotech Stocks To Watch After Positive Pre Market News
CORAL GABLES, FL / ACCESSWIRE / March 26, 2018 / Last week, the markets saw a major pullback amid fears of potential trade wars. But heading into Monday's opening bell, optimism is much more prevalent. The Wall Street Journal reported that U.S. and Chinese officials are working to improve U....
Source: ACCESSWIRE IA
Date: March, 26 2018 09:28
Akers Biosciences signs US distribution agreement with Diagnostica Stago; shares ahead 14% premarket
Akers Biosciences (NASDAQ: AKER ) has entered into a three-year National Distribution Agreement with Diagnostica Stago, Inc. for the sale of its rapid test for Heparin-induced thrombocytopenia (“HIT”) in the US. More news on: Akers Biosciences Inc., Healthcare stocks news, ...
Source: SeekingAlpha
Date: March, 26 2018 08:31

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-170.2740.26180.2780.25511,336,649
2018-08-160.26080.27410.2950.261,765,129
2018-08-150.220.25270.26850.214,287,727
2018-08-140.2750.3050.3150.274,340,180
2018-08-130.270.27120.27750.25352,093,502

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-17152,070526,75728.8691Cover
2018-08-16371,987614,84460.5010Short
2018-08-15576,7581,199,87248.0683Short
2018-08-14536,632936,23757.3180Short
2018-08-13413,333683,91260.4366Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AKER.


About Akers Biosciences Inc. (NASDAQ: AKER)

Logo for Akers Biosciences Inc. (NASDAQ: AKER)

Not available

 

Contact Information

 

 

Current Management

  • Thomas A. Nicolette / CEO, President

Current Share Structure

  • Market Cap: $4,352,052 - 05/14/2018
  • Authorized: 500,000,000 - 11/01/2017
  • Issue and Outstanding: 9,936,191 - 11/01/2017

 


Recent Filings from (NASDAQ: AKER)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 25 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 10 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 10 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 03 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 03 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 01 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 18 2018

 

 


Daily Technical Chart for (NASDAQ: AKER)

Daily Technical Chart for (NASDAQ: AKER)


Stay tuned for daily updates and more on (NASDAQ: AKER)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AKER)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AKER is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AKER and does not buy, sell, or trade any shares of AKER. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/